These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
202 related items for PubMed ID: 19920203
1. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH. Cancer Res; 2009 Dec 01; 69(23):8996-9002. PubMed ID: 19920203 [Abstract] [Full Text] [Related]
2. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. van Waterschoot RA, Lagas JS, Wagenaar E, Rosing H, Beijnen JH, Schinkel AH. Int J Cancer; 2010 Dec 15; 127(12):2959-64. PubMed ID: 21351274 [Abstract] [Full Text] [Related]
3. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine. Lagas JS, Damen CW, van Waterschoot RA, Iusuf D, Beijnen JH, Schinkel AH. Mol Pharmacol; 2012 Oct 15; 82(4):636-44. PubMed ID: 22767610 [Abstract] [Full Text] [Related]
4. Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. Choi YH, Suh JH, Lee JH, Cho IH, Lee MG. J Pharm Pharmacol; 2010 Aug 15; 62(8):1084-8. PubMed ID: 20663044 [Abstract] [Full Text] [Related]
5. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Hendrikx JJ, Lagas JS, Rosing H, Schellens JH, Beijnen JH, Schinkel AH. Int J Cancer; 2013 May 15; 132(10):2439-47. PubMed ID: 23090875 [Abstract] [Full Text] [Related]
6. A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice. van Waterschoot RA, Schinkel AH. Pharmacol Rev; 2011 Jun 15; 63(2):390-410. PubMed ID: 21490128 [Abstract] [Full Text] [Related]
7. The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice. Press RR, Buckle T, Beijnen JH, van Tellingen O. Cancer Chemother Pharmacol; 2006 Jun 15; 57(6):819-25. PubMed ID: 16163538 [Abstract] [Full Text] [Related]
8. Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pre-treatment with curcumin. Yan YD, Kim DH, Sung JH, Yong CS, Choi HG. Int J Pharm; 2010 Oct 31; 399(1-2):116-20. PubMed ID: 20727390 [Abstract] [Full Text] [Related]
9. From mouse to man: predictions of human pharmacokinetics of orally administered docetaxel from preclinical studies. Koolen SL, van Waterschoot RA, van Tellingen O, Schinkel AH, Beijnen JH, Schellens JH, Huitema AD. J Clin Pharmacol; 2012 Mar 31; 52(3):370-80. PubMed ID: 21505085 [Abstract] [Full Text] [Related]
10. Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats. Lee JH, Lee A, Oh JH, Lee YJ. Biopharm Drug Dispos; 2012 Nov 31; 33(8):474-86. PubMed ID: 22936118 [Abstract] [Full Text] [Related]
11. Intestinal first-pass metabolism by cytochrome p450 and not p-glycoprotein is the major barrier to amprenavir absorption. Dufek MB, Bridges AS, Thakker DR. Drug Metab Dispos; 2013 Sep 31; 41(9):1695-702. PubMed ID: 23821186 [Abstract] [Full Text] [Related]
12. P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. Tang SC, Kort A, Cheung KL, Rosing H, Fukami T, Durmus S, Wagenaar E, Hendrikx JJ, Nakajima M, van Vlijmen BJ, Beijnen JH, Schinkel AH. Mol Pharm; 2015 Oct 05; 12(10):3714-23. PubMed ID: 26317243 [Abstract] [Full Text] [Related]
13. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Kuppens IE, Bosch TM, van Maanen MJ, Rosing H, Fitzpatrick A, Beijnen JH, Schellens JH. Cancer Chemother Pharmacol; 2005 Jan 05; 55(1):72-8. PubMed ID: 15316750 [Abstract] [Full Text] [Related]
14. P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism. Dufek MB, Knight BM, Bridges AS, Thakker DR. Drug Metab Dispos; 2013 Mar 05; 41(3):642-50. PubMed ID: 23288866 [Abstract] [Full Text] [Related]
15. Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Schuetz EG, Umbenhauer DR, Yasuda K, Brimer C, Nguyen L, Relling MV, Schuetz JD, Schinkel AH. Mol Pharmacol; 2000 Jan 05; 57(1):188-97. PubMed ID: 10617694 [Abstract] [Full Text] [Related]
16. Danshen extract does not alter pharmacokinetics of docetaxel and clopidogrel, reflecting its negligible potential in P-glycoprotein- and cytochrome P4503A-mediated herb-drug interactions. Lee JH, Shin YJ, Kim HJ, Oh JH, Jang YP, Lee YJ. Int J Pharm; 2011 May 30; 410(1-2):68-74. PubMed ID: 21421030 [Abstract] [Full Text] [Related]
17. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. van Herwaarden AE, Wagenaar E, van der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, van der Valk MA, van Tellingen O, van der Hoorn JW, Rosing H, Beijnen JH, Schinkel AH. J Clin Invest; 2007 Nov 30; 117(11):3583-92. PubMed ID: 17975676 [Abstract] [Full Text] [Related]
18. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Bosch TM, Huitema AD, Doodeman VD, Jansen R, Witteveen E, Smit WM, Jansen RL, van Herpen CM, Soesan M, Beijnen JH, Schellens JH. Clin Cancer Res; 2006 Oct 01; 12(19):5786-93. PubMed ID: 17020985 [Abstract] [Full Text] [Related]
19. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JH, Beijnen JH, van Tellingen O. Cancer Res; 2002 Nov 01; 62(21):6158-64. PubMed ID: 12414642 [Abstract] [Full Text] [Related]
20. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans. van Zuylen L, Verweij J, Nooter K, Brouwer E, Stoter G, Sparreboom A. Clin Cancer Res; 2000 Jul 01; 6(7):2598-603. PubMed ID: 10914699 [Abstract] [Full Text] [Related] Page: [Next] [New Search]